Table 3.
Clinical Outcomes Of NBS Or SCS By Intravenous Injection As Initial Treatment (Grouped By Further Treatment), Stratified By PaCO2
| Dose-Escalation Group (NBS Initial) | Dose Maintenance Or Reduction Group (NBS Initial) | Dose Maintenance Or Escalation Group (SCS Initial) | Dose-Reduction Group (SCS Initial) | P-Value | ||
|---|---|---|---|---|---|---|
| (N=756) | (N=1443) | (N=404) | (N=518) | |||
| PaCO2 ≤ 50 (mmHg) | Intubation rate | 7 (0.9%) | 10 (0.7%) | 2 (0.5%) | 3 (0.6%) | 0.37 |
| Mortality | 7 (0.9%) | 6 (0.4%) | 5 (1.2%) | 2 (0.4%) | <0.001 | |
| Rate of new-onset pneumonia | 13 (1.7%) | 10 (0.7%) | 8 (2.0%) | 10 (1.9%) | 0.19 | |
| PaCO2 > 50 (mmHg) | Intubation rate | 17 (2.2%) | 16 (1.1%) | 11 (2.7%) | 10 (1.9%) | 0.001 |
| Mortality | 7 (0.9%) | 3 (0.2%) | 6 (1.5%) | 4 (0.8%) | 0.005 | |
| Rate of new-onset pneumonia | 10 (1.3%) | 5 (0.3%) | 3 (0.7%) | 5 (1.0%) | 0.81 |
Note: P-value is adjusted by site.